On April 03, 2024 Aanastra, Inc., a biopharmaceutical company focused on developing novel RNA therapeutics targeting Tumor Suppressors and Oncogenes, reported poster presentations at the 2024 American Association for Cancer Research (AACR) (Free AACR Whitepaper), taking place April 5-10, 2024, in San Diego, CA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AACR poster presentation details are below:
Title: " In vivo rescue of p53 tumor suppressor function with ADGN-531 across Pan-p53 alterations "
Session Title: Mechanisms of Drug Action
Location: Poster Section 26, Board Number 17
Abstract Number: 640
Date/Time: Sunday Apr 7, 2024 1:30 PM – 5:00 PM
Presenting Author: DIVITA Gilles, PhD
Title: " Selective deletion of the KRAS mutant gene with ADGN-121 and ADGN-122 peptide-RNA nanoparticles: A new strategy to overcome acquired resistance to KRASG12C and KRASG12D small molecule inhibitors "
Session Title: Vector Systems, Oncolytic Virotherapy, and Gene Therapy
Location: Poster Section 27, Board Number 3
Abstract Number: 7236
Date/Time: Wednesday Apr 10, 2024 9:00 AM – 12:30 PM
Presenting Author: DIVITA Gilles, PhD
Title: " Peptide-mRNA complex mediated restoration of BRCA-1 tumor suppressor function in BRCA-1 mutated cancers as a new therapeutic strategy "
Session Title: Vector Systems, Oncolytic Virotherapy, and Gene Therapy
Location: Poster Section 27, Board Number 4
Abstract Number: 7237
Date/Time: Wednesday Apr 10, 2024 9:00 AM – 12:30 PM
Presenting Author: DIVITA Gilles, PhD
More information can be found on the AACR (Free AACR Whitepaper) meeting website.
(Press release, AANASTRA, APR 3, 2024, View Source [SID1234662315])